The vopimetostat data and regulatory engagement plans are the primary value drivers. Monitor FDA feedback on accelerated approval path and Phase 3 initiation in 1H 2027. The cash runway appears sufficient through key milestones. The G&A spike from equity modifications is non-recurring but the R&D burn rate is rising.
Drugs in focus
ERAS-0015
◆ Mixed Named in this press release- Impact
- Phase
- Phase 1
- Time to market
- ~3-5 years, assuming registration-enabling trials initiate in 2027 and a potential approval by ~2029-2030
- Next catalyst
- None dated
What to watchERAS-0015 Phase 1 data is genuinely strong (57-62% response rates in difficult-to-treat tumors) but the stock carries heavy legal baggage, a securities class action and patent-infringement allegations from Revolution Medicines. The stock recovered from its April 48% crash to ~$18; watch for the August 10, 2026 lead-plaintiff deadline and any developments in the Revolution Medicines patent dispute, which could swing shares sharply. The registration-enabling trial initiations in H1 2027 are the next major de-risking catalyst.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 9 $22.74entry
- T+1 · 7d ago +6.86%α +7.23% · $24.30
- T+5 · 17h ago +6.29%α +7.98% · $24.17
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tango Therapeutics reported Q3 2026 net loss of $68.4M ($0.39/share) vs net income of $15.9M ($0.14/share) in Q3 2025, driven by higher R&D and G&A expenses and the end of Gilead collaboration revenue. Cash stood at $977.5M. The key catalyst was promising Phase 1/2 data for vopimetostat plus daraxonrasib in pancreatic cancer (82% ORR, 88% 9-month PFS), with plans for a Phase 3 registrational study in 1H 2027 and potential accelerated approval discussions.
Key Financial Metrics
Key Facts
- Net loss Q3 2026: $68.4M ($0.39/share) vs net income $15.9M ($0.14/share) in Q3 2025
- Cash, cash equivalents and marketable securities: $977.5M as of Sep 30, 2026
- Collaboration revenue: $0 in Q3 2026 vs $53.8M in Q3 2025 (Gilead deal ended)
- R&D expenses: $48.9M in Q3 2026 vs $30.8M in Q3 2025
- G&A expenses: $29.2M in Q3 2026 vs $8.9M in Q3 2025 (includes equity award modifications for former executives)
- Phase 1/2 data for vopimetostat + daraxonrasib: 82% ORR, 88% 9-month PFS in 2L/3L pancreatic cancer
- Registrational Phase 3 study planned in front-line MTAP-deleted pancreatic cancer in 1H 2027
- Company plans to discuss accelerated approval in 2L pancreatic cancer with regulators
- Strategic reprioritization to focus on PRMT5-targeted therapies
Financial Impact
Net loss widened by $84.3M YoY; cash burn rate increased; no revenue in the quarter
Risk Factors
- No current revenue; fully dependent on pipeline success
- Phase 3 trial may fail to replicate Phase 1/2 results
- Regulatory path for accelerated approval uncertain
- Rising R&D and G&A expenses increase cash burn
- Competition from other PRMT5 and RAS-targeted therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398261 |
Track record
27 reports on TNGX
3 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +29.28% at T+60 after the Jun 8, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.22 Now $24.17 +0.21% settles Feb 16
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.50 Now $24.17 +1.35% settles Feb 12
- Nov 9, 20267d ago Press Release Neutral 5/10 Viewing Entry $22.74 Now $24.17 +6.29% settles Feb 5
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $21.50 Now $24.17 +12.42% settles Feb 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $20.87 Now $24.17 +15.81% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $23.34 Now $24.17 +3.56% settles Jan 21
- Aug 11, 202613w ago 8-K Bearish 6/10 Entry $25.58 to $23.18 Now $24.17 +5.51% ▲ +9.38% +4.51% vs SPY
- Aug 11, 202613w ago 8-K Bullish 7/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers